BHCM
CRL icon

Boulder Hill Capital Management’s Charles River Laboratories CRL Stock Holding History

Boulder Hill Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,700
Closed -$1.02M – 158
2021
Q4 		$1.02M Buy
+2,700
New +$1.05M 0.98% 11

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Boulder Hill Capital Management's CRL Position: Q1 2022 in Review

Boulder Hill Capital Management sold out of Charles River Laboratories (CRL) in Q1 2022, closing a stake of 2,700 shares — an estimated $1.02M sold.

Boulder Hill Capital Management first reported a position in CRL in Q4 2021 and held it in 1 quarter. The position peaked at $1.02M in Q4 2021. 644 funds tracked by Wall St. Rank hold CRL as of Q1 2022.

  • Boulder Hill Capital Management reported no remaining Charles River Laboratories position as of Q1 2022 after selling out during the quarter.
  • Boulder Hill Capital Management sold 2,700 Charles River Laboratories shares in Q1 2022, an estimated $1.02M.
  • Boulder Hill Capital Management first reported a position in Charles River Laboratories in Q4 2021 and held it in 1 quarter.
  • Boulder Hill Capital Management's Charles River Laboratories position peaked at $1.02M in Q4 2021.
  • 644 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2022.

Based on Boulder Hill Capital Management's 13F filing for Q1 2022, filed 12 May 2022.